Sanofi deal will bank roll Denali's indication expansion

Sanofi (Euronext:SAN; NYSE:SNY) paid Denali Therapeutics Inc. (NASDAQ:DNLI) $125 million in cash up front to co-develop multiple receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitors to treat neurological and systemic inflammatory diseases. Sanofi will cover most of the clinical development costs, which Denali

Read the full 421 word article

User Sign In